- Report
- July 2023
- 115 Pages
Global
From €3938EUR$4,500USD£3,423GBP
- Report
- November 2023
- 276 Pages
Global
€4371EUR$4,995USD£3,800GBP
- Report
- September 2024
- 211 Pages
Global
From €3895EUR$4,450USD£3,385GBP
- Report
- July 2024
- 32 Pages
Global
From €608EUR$695USD£529GBP
- Report
- July 2023
- 45 Pages
Global
From €608EUR$695USD£529GBP
- Report
- May 2023
- 60 Pages
Global
From €608EUR$695USD£529GBP
- Report
- November 2022
- 30 Pages
Global
From €608EUR$695USD£529GBP
- Report
- October 2025
- 82 Pages
Qatar
From €4245EUR$4,850USD£3,690GBP
From €4245EUR$4,850USD£3,690GBP
From €4245EUR$4,850USD£3,690GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2626EUR$3,000USD£2,282GBP
Phase II Clinical Trials are a critical step in the drug development process. They are designed to evaluate the safety and efficacy of a drug or medical device in a larger group of people than Phase I trials. The Phase II trial market is a subset of the larger clinical trial market, and is composed of pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutions.
Phase II trials are typically conducted in multiple countries, and involve a larger number of participants than Phase I trials. They are designed to assess the efficacy of a drug or medical device in a larger population, and to identify any potential side effects. The results of Phase II trials are used to determine whether a drug or medical device should proceed to Phase III trials.
Some of the companies in the Phase II trial market include Pfizer, Merck, Novartis, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Eli Lilly, and Sanofi. CROs such as Parexel, Quintiles, and Covance also play a significant role in the Phase II trial market. Show Less Read more